TEVJF Statistics
Total Valuation
Teva Pharmaceutical Industries has a market cap or net worth of 24.72 billion. The enterprise value is 41.00 billion.
| Market Cap | 24.72B |
| Enterprise Value | 41.00B |
Important Dates
The next estimated earnings date is Wednesday, January 29, 2025.
| Earnings Date | Jan 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.13B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.33, with an EV/FCF ratio of 29.97.
| EV / Earnings | -42.75 |
| EV / Sales | 2.44 |
| EV / EBITDA | 8.33 |
| EV / EBIT | 10.99 |
| EV / FCF | 29.97 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 3.02.
| Current Ratio | 0.89 |
| Quick Ratio | 0.49 |
| Debt / Equity | 3.02 |
| Debt / EBITDA | 3.92 |
| Debt / FCF | 14.09 |
| Interest Coverage | 3.69 |
Financial Efficiency
Return on equity (ROE) is -17.52% and return on invested capital (ROIC) is 8.72%.
| Return on Equity (ROE) | -17.52% |
| Return on Assets (ROA) | 5.56% |
| Return on Capital (ROIC) | 8.72% |
| Revenue Per Employee | 453,297 |
| Profits Per Employee | -25,919 |
| Employee Count | 36,472 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +135.37% in the last 52 weeks. The beta is 0.87, so Teva Pharmaceutical Industries's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +135.37% |
| 50-Day Moving Average | 16.40 |
| 200-Day Moving Average | 11.04 |
| Relative Strength Index (RSI) | 53.45 |
| Average Volume (20 Days) | 361 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.89 |
Income Statement
In the last 12 months, Teva Pharmaceutical Industries had revenue of 16.77 billion and -959.00 million in losses. Loss per share was -0.86.
| Revenue | 16.77B |
| Gross Profit | 8.36B |
| Operating Income | 3.73B |
| Pretax Income | -528.00M |
| Net Income | -959.00M |
| EBITDA | 4.79B |
| EBIT | 3.73B |
| Loss Per Share | -0.86 |
Balance Sheet
The company has 3.32 billion in cash and 19.28 billion in debt, giving a net cash position of -15.96 billion.
| Cash & Cash Equivalents | 3.32B |
| Total Debt | 19.28B |
| Net Cash | -15.96B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.38B |
| Book Value Per Share | 5.35 |
| Working Capital | -1.48B |
Cash Flow
In the last 12 months, operating cash flow was 1.86 billion and capital expenditures -488.00 million, giving a free cash flow of 1.37 billion.
| Operating Cash Flow | 1.86B |
| Capital Expenditures | -488.00M |
| Free Cash Flow | 1.37B |
| FCF Per Share | n/a |
Margins
Gross margin is 49.84%, with operating and profit margins of 22.24% and -5.72%.
| Gross Margin | 49.84% |
| Operating Margin | 22.24% |
| Pretax Margin | -3.15% |
| Profit Margin | -5.72% |
| EBITDA Margin | 28.54% |
| EBIT Margin | 22.24% |
| FCF Margin | 8.16% |
Dividends & Yields
Teva Pharmaceutical Industries does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | -0.87% |
| Earnings Yield | -3.88% |
| FCF Yield | 5.53% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teva Pharmaceutical Industries has an Altman Z-Score of 0.42. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.42 |
| Piotroski F-Score | n/a |